CBD Life Sciences Expands Global Footprint with Strategic Manufacturing Partnerships in Colombia and U.S.

CBD Life Sciences Inc. (搜索)搜索该公司 (OTC PINK:CBDL) has announced two significant manufacturing partnerships that position the company for substantial growth in both international and domestic CBD查看药品详情 markets.

Colombian Partnership Targets Latin American Expansion

CBDL has secured a manufacturing agreement with Thallos (搜索)搜索该词条, a prominent South American company headquartered in Colombia. Under this partnership, CBDL will handle the complete production, packaging, and labeling of high-potency CBD查看药品详情 products exclusively for Thallos.

The product line includes 2,000mg Pain Cream Salves in Mint and Cinnamon varieties, along with a 2,000mg CBD查看药品详情 Tincture. All manufacturing will take place at CBDL's U.S.-based facilities, allowing the company to maintain strict quality control standards.

This strategic move comes as South America's CBD查看药品详情 market is projected to exceed $4.9 billion by 2028, with Colombia emerging as a key player in the region. The partnership addresses specific challenges faced by Colombian companies like Thallos (搜索)搜索该词条, which currently struggle with U.S. tariffs and regulatory hurdles when importing CBD products.

"This partnership is a game-changer for CBDL," said Lisa Nelson, CEO of CBD Life Sciences Inc. (搜索)搜索该公司 "By strategically positioning ourselves as the manufacturing engine for a growing South American brand, we're opening the door to scalable, recurring revenue and strengthening our position as a dominant force in the global CBD查看药品详情 supply chain."

Domestic Growth Through Retail Partnership

In a parallel development, CBDL has also established a manufacturing partnership with Jeannie in a Bottle (搜索)搜索该词条, an Arizona-based CBD查看药品详情 company with a national retail footprint spanning over 100 gas stations and convenience stores across the United States.

This collaboration will see CBDL formulating and manufacturing premium CBD查看药品详情 products exclusively for Jeannie in a Bottle (搜索)搜索该词条, leveraging the latter's established consumer base and retail distribution network. The agreement is expected to generate consistent monthly reorders, creating a stable revenue pipeline for CBDL.

"This partnership is a win-win - not just for CBDL and Jeannie in a Bottle (搜索)搜索该词条, but for shareholders and customers alike," Nelson explained. "We're stepping into a high-velocity retail environment with a proven brand, and bringing our own formulation and production strengths to the table. This is the kind of alignment that accelerates revenue, reputation, and results."

Strategic Implications for Growth

The dual partnerships represent a significant step in CBDL's expansion strategy, providing the company with:

1. Diversified Revenue Streams: By manufacturing for both international and domestic partners, CBDL reduces market dependency while creating multiple channels for growth.

2. Enhanced Production Efficiency: Increased manufacturing volume allows CBDL to optimize its production facilities and potentially achieve economies of scale.

3. Market Access: The partnerships provide entry points to both the rapidly growing Latin American market and the established U.S. retail sector without requiring CBDL to build its own distribution networks.

4. Brand Positioning: As a manufacturing partner for established brands, CBDL strengthens its reputation as a quality producer in the CBD查看药品详情 industry.

Company Background

CBD Life Sciences Inc. (搜索)搜索该公司 develops and distributes CBD查看药品详情-based wellness products through retail, e-commerce, and wholesale channels. The company has also expanded into functional mushroom products through its Mushroom Madness brand.

With these new manufacturing partnerships, CBDL appears positioned to capitalize on growing demand for CBD查看药品详情 products across multiple markets, potentially setting the stage for significant revenue growth in 2025 and beyond.